Galectin-3 Mediates Vascular Dysfunction in Obesity by Regulating NADPH Oxidase 1
Arteriosclerosis, Thrombosis, and Vascular Biology · 2023
DOI: 10.1161/atvbaha.123.319476 ↗Kurz gefasst
Fachartikel in der Zeitschrift Arteriosclerosis, Thrombosis, and Vascular Biology, 2023. Verfasst von Caleb A Padgett und 15 weiteren Autor:innen. Beteiligte Einrichtung: Vascular Biology Center (C.A.P., R.K.P., A.C.S., C.L.R., S.B.H., H.G.S., Z.L.C., M.A.W., J.D.M., D.J.R.F., D.W.S.), Medical College of Georgia, Augus…. Hauptthemen laut MEDLINE: Cardiovascular Diseases, Hyperglycemia, Hypertension. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS.
Abstract (Originalsprache)
BACKGROUND: Obesity is associated with increased risk of cardiovascular disease, but underlying mechanisms remain elusive. Metabolic dysfunction, especially hyperglycemia, is thought to be a major contributor, but how glucose impacts vascular function is unclear. GAL3 (galectin-3) is a sugar-binding lectin upregulated by hyperglycemia, but its role as a causative mechanism of cardiovascular disease remains poorly understood. Therefore, the objective of this study was to determine the role of GAL3 in regulating microvascular endothelial vasodilation in obesity. METHODS: GAL3 was measured and found to be markedly increased in the plasma of overweight and obese patients, as well as in the microvascular endothelium of diabetic patients. To investigate causative mechanisms in cardiovascular disease, mice deficient in GAL3 were bred with obese db/db mice to generate lean, lean GAL3 knockout, obese, and obese GAL3 knockout genotypes. Endothelial cell–specific GAL3 knockout mice with novel AAV-induced obesity recapitulated whole-body knockout studies to confirm cell specificity. RESULTS: Deletion of GAL3 did not alter body mass, adiposity, or plasma indices of glycemia and lipidemia, but levels of plasma reactive oxygen species as assessed by plasma thiobarbituric acid reactive substances were normalized in obese GAL3 knockout mice. Obese mice exhibited profound endothelial dysfunction and hypertension, both of which were rescued by GAL3 deletion. Isolated microvascular endothelial cells from obese mice had increased expression of NOX1 (nicotinamide adenine dinucleotide phosphate oxidase 1), which we have previously shown to contribute to increased oxidative stress and endothelial dysfunction, which was normalized in microvascular endothelium from mice lacking GAL3. Cell-specific deletion confirmed that endothelial GAL3 regulates obesity-induced NOX1 overexpression and subsequent microvascular function. Furthermore, improvement of metabolic syndrome by increasing muscle mass, improving insulin signaling, or treating with metformin decreased microvascular GAL3, and thereby NOX1, expression levels. CONCLUSIONS: Deletion of GAL3 normalizes microvascular endothelial function in obese db/db mice, likely through a NOX1-mediated mechanism. Pathological levels of GAL3, and in turn NOX1, are amenable to improvements in metabolic status, presenting a potential therapeutic target to ameliorate pathological cardiovascular consequences of obesity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Vascular Biology Center (C.A.P., R.K.P., A.C.S., C.L.R., S.B.H., H.G.S., Z.L.C., M.A.W., J.D.M., D.J.R.F., D.W.S.), Medical College of Georgia, Augusta University.
- Department of Physiology (W.B.B., C.C.D., R.A.H., M.W.B., D.W.S.), Medical College of Georgia, Augusta University.
- Georgia Prevention Institute (C.C.D., R.A.H.), Medical College of Georgia, Augusta University.
- Department of Surgery (B.B.A.), Medical College of Georgia, Augusta University.
- Department of Pharmacology and Toxicology (D.J.R.F.), Medical College of Georgia, Augusta University.
ORCID-Profile: Caleb A Padgett, Róbert K Bátori, Andrew C Speese, Cassandra C Derella, Hunter G Sellers, Zachary L Corley, Madison A West, Brittany B Ange, Ryan A Harris, Michael W Brands, David J R Fulton, David W Stepp
Förderung
- NHLBI NIH HHS
Zitieren
APA
Padgett, C. A., Bátori, R. K., Speese, A. C., Rosewater, C. L., Bush, W. B., Derella, C. C., Haigh, S. B., Sellers, H. G., Corley, Z. L., West, M. A., Mintz, J. D., Ange, B. B., Harris, R. A., Brands, M. W., Fulton, D. J. R., & Stepp, D. W. (2023). Galectin-3 Mediates Vascular Dysfunction in Obesity by Regulating NADPH Oxidase 1. Arteriosclerosis, Thrombosis, and Vascular Biology. https://doi.org/10.1161/atvbaha.123.319476
Vancouver
Padgett CA, Bátori RK, Speese AC, Rosewater CL, Bush WB, Derella CC, et al. Galectin-3 Mediates Vascular Dysfunction in Obesity by Regulating NADPH Oxidase 1. Arteriosclerosis, Thrombosis, and Vascular Biology. 2023. doi:10.1161/atvbaha.123.319476
BibTeX
@article{Padgett2023,
author = {Padgett, Caleb A and Bátori, Róbert K and Speese, Andrew C and Rosewater, Cody L and Bush, Weston B and Derella, Cassandra C and Haigh, Stephen B and Sellers, Hunter G and Corley, Zachary L and West, Madison A and Mintz, James D and Ange, Brittany B and Harris, Ryan A and Brands, Michael W and Fulton, David J R and Stepp, David W},
title = {Galectin-3 Mediates Vascular Dysfunction in Obesity by Regulating NADPH Oxidase 1},
journal = {Arteriosclerosis, Thrombosis, and Vascular Biology},
year = {2023},
doi = {10.1161/atvbaha.123.319476}
}
EUVIMED